Terms ending in 2031
Interpace Diagnostics Corporation
Every in-force patent on Interpace Diagnostics Corporation's record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,150,999 | Mirnas as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms In force · High confidence | Interpace Diagnostics, LLC | In force | High confidence | |
| US 11,118,231 | Mirnas as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms In force · High confidence | Interpace Diagnostics, LLC | In force | High confidence |
2 of 2 patents shown. Soonest term end first, then patent number.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.